Search results :

Nevirapine

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: J05AG01

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Rash postmarketing — 4% - 24% 1.5% - 14.9% x x x x x x x x x x x x x x x x
Liver function test abnormal common, 1.2% - 6.7% 0.9% - 1.5% x x x x x
Alanine aminotransferase increased common x x x x
Headache common, 0.7% - 4% 0.4% - 1% x x x x x x x x x x x x x x x x
Abdominal pain common, 0.1% - 3% 0% - 1% x x x x x x x x x x x x x x x x
Diarrhoea common, 0.2% - 4% 0.5% - 1% x x x x x x x x x x x x x x x x
Nausea common, 0.5% - 9% 1% - 4% x x x x x x x x x x x x x x x x
Hepatotoxicity common, 2% - 2.4% x x x x x x x x x x
Myalgia postmarketing — 0.2% - 1.2% 0% - 2% x x x x x x x x x x x x x x
Drug eruption uncommon x x
Blood pressure increased uncommon x x x x
Blood phosphorus decreased uncommon x x x x
Agranulocytosis postmarketing — 0.4% - 3.3% 0% - 3% x x x x x x x x x x x x x x x x
Fatigue postmarketing — 0.2% - 5% 0.3% - 4% x x x x x x x x x x x x x x x x
Toxic epidermal necrolysis postmarketing, uncommon x x x x x x x x x x x x x x x x
Stevens-Johnson syndrome postmarketing — 0.3% x x x x x x x x x x x x x x x x
Anaphylactic shock postmarketing — common x x x x x x x x x x x x x x x x
Anaemia postmarketing — 7% - 7.3% x x x x x x x x x x x x x x x x
Angioedema postmarketing — common x x x x x x x x x x x x x x x x
Arthralgia postmarketing — 2% x x x x x x x x x x x x x x x x
Blister postmarketing x x x x x x x x x x x x x
Conjunctivitis postmarketing x x x x x x x x x x x x x
Oedema postmarketing x
Eosinophilia postmarketing, uncommon x x x x x x x x x x x x x x x x
Body temperature increased postmarketing — 1% - 2% x x x x x x x x x x x x x x x x
Hepatitis postmarketing — 1.2% - 4% x x x x x x x x x x x x x x x x
Hypersensitivity postmarketing, common x x x x x x x x x x x x x x x x
Jaundice postmarketing, uncommon x x x x x x x x x x x x x x x x
Neutropenia postmarketing, 8.9% - 9% x x x x x x x x x x x x x x
Paraesthesia postmarketing x x x x x x x x x x x x
Rhabdomyolysis postmarketing x x x x x x x x x
Ulcerative stomatitis postmarketing x x x x x x x x x x x x x
Urticaria postmarketing, uncommon x x x x x x x x x x x x x x x x
Vomiting postmarketing, common x x x x x x x x x x x x x x x x
Hepatic failure postmarketing, rare x x x x x x x x x x x x x x x x
Oral lesion postmarketing x x x x x x x x x x x x x
Hepatitis cholestatic postmarketing x x x x x x x x x x x x x
Hepatic necrosis postmarketing x x x x x x x x x x x x x
Malaise postmarketing x x x x x x x x x x x x x
Ache postmarketing x x x x x x x x x x x x x
Paraesthesia skin postmarketing x
Bullous eruption postmarketing x x x x x x x x x x x x x
Hepatitis fulminant rare x x x x x
Lymphadenopathy postmarketing x x x x x x x x x x x x x x x x
Face oedema postmarketing x x x x x x x x x x x x
Hypersensitive syndrome postmarketing x x x x x x x x x x x x x x
Drug interaction postmarketing x x x x x x x x x
Somnolence postmarketing x x x x x x x x x x x x x
Congenital anomaly x
Anorexia x x
Autoimmune disorder x x
Bone disorder x
Connective tissue disorder x x x
Dermatitis exfoliative x
Erythema multiforme x
Erythema nodosum x
Gastrointestinal disorder x x x x
Basedow's disease x x
Hepatitis toxic x
Hypercholesterolaemia x x
Hyperglycaemia x x
Hypertriglyceridaemia x x
Hypertrophy of breast x x
Immune system disorder x x x x
Inflammation x x
Insulin resistance x x
Lipodystrophy x x
Liver disorder x
Necrosis x
Nervous system disorder x x x x
Opportunistic infection x x
Pancreatitis x x x
Neuropathy peripheral x x x
Pruritus x x x x x x x x x x x x x x x x
Renal failure x x
Thrombocytopenia x x x x x x x x x x x x
Ulcer x
Erythema x
Gamma-glutamyltransferase increased x x x x
Aspartate aminotransferase increased x x x x
Liver injury x
Unspecified disorder of skin and subcutaneous tissue x x x x
Rash erythematous x x x x x x x x x x x x x x x x
Hepatic enzyme increased x x x x
Skin exfoliation x
Vertical infection transmission x
Hepatobiliary disease x x x x
Hepatitis acute x
Rash maculo-papular x x
Transaminases increased x x x x
Buffalo hump x x
Chronic hepatitis B x
Surgical intervention x x
Hyperlactacidaemia x x
Blood and lymphatic system disorders x x x x
Fat redistribution x x x
Rash papular x
Hypertransaminasaemia x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

NEVIRAPINE

Side effects:41
Source:FDA Structured Product Label

NEVIRAPINE / VIRAMUNE

Side effects:42
Source:FDA

NEVIRAPINE / VIRAMUNE

Side effects:41
Source:FDA

NEVIRAPINE / VIRAMUNE

Side effects:42
Source:FDA

NEVIRAPINE

Side effects:43
Source:FDA Structured Product Label

NEVIRAPINE

Side effects:43
Source:FDA Structured Product Label

NEVIRAPINE

Side effects:43
Source:FDA Structured Product Label

nevirapine

Side effects:43
Source:FDA Structured Product Label

NEVIRAPINE

Side effects:43
Source:FDA Structured Product Label

NEVIRAPINE / VIRAMUNE

Side effects:43
Source:FDA

NEVIRAPINE

Side effects:47
Source:FDA Structured Product Label

NEVIRAPINE / VIRAMUNE

Side effects:54
Source:Health Canada

Nevirapine / Nevirapine

Side effects:58
Source:medicines.org.au

nevirapine / nevirapine

Side effects:60
Source:EMA

nevirapine / nevirapine

Side effects:61
Source:EMA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label